Volume 3.40 | Oct 13

Cord Blood News 3.40, October 13, 2011
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cord Blood News on Twitter

Changing Criteria for Umbilical Cord Transplantation Could Improve Survival Rates
Selecting better matched recipients and donors for umbilical cord blood transplantation could substantially reduce transplant-related deaths, according to a new study. [Press release from the Medical College of Wisconsin discussing online prepublication in The Lancet Oncology] Press Release | Abstract


PUBLICATIONS (Ranked by Impact Factor of the Journal)

Induced Immune Tolerance for Kidney Transplantation
In the current proof-of-concept study, 12 patients who received HLA-matched kidney transplants received a donor-cell infusion of highly enriched CD34+ hematopoietic progenitor cells mixed with CD3+ T cells, and a conditioning regimen of total lymphoid irradiation and anti–T-cell antibodies according to a protocol described in detail in a previous case report of the successful induction of tolerance. [N Engl J Med] Abstract | Press Release

Impaired Functionality and Homing of Fancg-Deficient Hematopoietic Stem Cells
Scientists have examined the role of the nuclear Fanconi Anemia core complex gene Fancg in the functionality of hematopoietic stem cells. [Hum Mol Genet] Abstract

Intracerebroventricular Administration of Human Umbilical Cord Blood Cells Delays Disease Progression in Two Murine Models of Motor Neuron Degeneration
In an attempt to improve the potential efficacy of human cord blood mononuclear cells (HuCB-MNCs) in the central nervous system, researchers examined the effect and distribution of Hoechst 33258-labeled HuCB-MNCs after a single bilateral intracerberoventricular injection in two models of motor neuron degeneration, the transgenic SOD1G93A and wobbler mice. [Rejuvenation Res] Abstract

The Anti-Tumour Activity of Allogeneic Cytokine-Induced Killer Cells in Patients Who Relapse After Allogeneic Transplant for Haematological Malignancies
Researchers performed a Phase I/II clinical trial to study the feasibility, toxicity and efficacy of allogeneic cytokine-induced killer cell expansion, and treatment for patients with haematological malignancies who relapsed after allogeneic haemopoietic stem cell transplantation. [Bone Marrow Transplant] Abstract

Predicting Overall Viability of Cord Blood Harvests
Researchers retrospectively analyzed white blood cell (WBC) viability from 9918 cord blood collections harvested from 2003 to 2010 to determine if collection volume and time to freezing had a significant effect on WBC viability. [Transfusion] Abstract

High Cord Blood Levels of the T-Helper 2-Associated Chemokines CCL17 and CCL22 Precede Allergy Development During the First 6 Years of Life
The aim of the study was to determine whether cord blood T-helper 1 (Th1)- and Th2-associated chemokine levels are associated with allergy development during the first 6 y of life, allowing assessment of respiratory allergic symptoms usually developing in this period. [Pediatr Res] Abstract

Chromosomal Stability During Ex Vivo Expansion of UCB CD34+ Cells
In this study, scientists evaluated genetic stability of umbilical cord blood (UCB)-derived CD34+ cells during ex vivo culture, based on karyotype analysis, as well as its effect on cell proliferation characteristics. [Cell Prolif] Abstract

Angiopoietin-Like-2 and -3 Act Through Their Coiled-Coil Domains to Enhance Survival and Replating Capacity of Human Cord Blood Hematopoietic Progenitors
Investigators assessed purified recombinant endotoxin-free human angiopoietin-like (ANGPTL)-2 Coiled-Coil (CC), -3, -3CC, -3 fibrinogen-like domain, -4, -4CC, -5CC, -6 and -7 for effects on proliferation and survival of hematopoietic progenitor cells from human cord blood. [Blood Cells Mol Dis] Abstract

Unrelated Cord Blood Transplantation After Myeloablative Conditioning Regimen in Adolescent and Young Adult Patients with Hematologic Malignancies: A Single Institute Analysis
Scientists report the results of unrelated cord blood transplantation after myeloablative conditioning regimen in 16 patients with hematologic malignancies from 15 to 20 years old. [Leuk Res] Abstract

Fludarabine, Melphalan, Thiotepa and ATG Conditioning for Unrelated Cord Blood Transplantation
Researchers evaluated the toxicity and outcomes of a conditioning regimen consisting of melphalan 140 mg/m2 (day -8), thiotepa 10 mg/kg (day -7), fludarabine 160 mg/m2 over 4 days (days -6 to -3), and rabbit ATG 1.25 mg/kg (day -4) and 1.75 mg/kg (day -3). [Leuk Lymphoma] Abstract



PerkinElmer’s ViaCord® Cord Blood Banking Business to Expand Stem Cell Harvesting Capabilities
PerkinElmer, Inc. announced that its family cord blood banking business, ViaCord®, will now offer families the ability to extract stem cells from the tissue surrounding the umbilical cord vessels, a very rich source of mesenchymal stem cells. [PerkinElmer, Inc.] Press Release

Cord Blood America, Inc. to Evaluate Possible Strategic Alternatives
Cord Blood America, Inc. announced that its Board of Directors will conduct a process to explore and evaluate strategic alternatives for Cord Blood America to enhance shareholder value. [Cord Blood America, Inc.] Press Release

Cryo-Save Group N.V. Is Proud to Announce a Step Forward in Cord Blood Stem Cell Education for Gynecologists: The Italian Case
The Italian Association of Hospital Obstetricians and Gynecologists (AOGOI) entered into an agreement with Cryo-Save to launch LIVECORD project. The LIVECORD project is dedicated to providing education and disseminating accurate information on the cryopreservation of stem cells and their current use in clinical therapeutic treatments to medical and paramedical staff. [PR Newswire] Press Release

U.S. Cord Blood Supply Lacking, GAO Says
The national supply of umbilical cord blood is not growing as fast as it could, in part because of competition from private blood banks and a slowdown in growth in the cord blood market, according to a new report from the Government Accountability Office (GAO). [MedPage Today] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW Phacilitate Cell & Gene Therapy Forum 2012
January 30-February 1, 2012
Washington, United States

our events page to see a complete list of events in the cord blood community.

Lab Technologist – Tissue Culture (STEMCELL Technologies) 

Research and Development Technologist, hPSC Media (STEMCELL Technologies) 

Scientist (iPSC) (STEMCELL Technologies)

Contract Assay Service Technologist (STEMCELL Technologies)

Lab Technologist – Pluripotent Stem Cells (STEMCELL Technologies)

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Quality Control Technologist – Cell Separation (STEMCELL Technologies)

Senior Laboratory Technician – Life Sciences (Matchtech)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally:
United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Cord Blood News: Archives | Events | Contact Us